Skip to main navigation

Tests
- Diseases areas
  Cancer
  Other
  - Interstitial lung disease
- Products
  Thyroid Cancer
  - Afirma Genomic Sequencing Classifier
  Prostate Cancer
  - Decipher Prostate Genomic Classifier
  Breast Cancer
  - Prosigna Breast Cancer Assay
  Interstitial Lung Disease
  - Envisia Genomic Classifier
  Bladder Cancer
  - Decipher Bladder Genomic Classifier
- Pipeline
- Publications
Partner Services
- Biopharma services
- IVD services
Company
- About us
- Contact
News & Events
- News
  - Press releases
  - In the news
- Events
Careers
- Culture
- Job Openings
Investors

Tests
Cancer

Thyroid cancer

Prostate cancer

Lung cancer

Breast cancer

Bladder cancer

Other

Interstitial lung disease

Portfolio and test expansion
Thyroid Cancer

Afirma Genomic Sequencing Classifier

Prostate Cancer

Decipher Prostate Genomic Classifier

Breast Cancer

Prosigna Breast Cancer Assay

Interstitial Lung Disease

Envisia Genomic Classifier

Bladder Cancer

Decipher Bladder Genomic Classifier

Instructions for use

Quality certificates

Safety data sheet

Enabling global access
Portfolio and test expansion

Enabling global access

MRD technology

Who we are
Partner Services
- Biopharma services
- IVD services
Company
- About us
- Contact
Who we are

Leadership

Corporate recognition

Culture
News & Events
- News
- Events
Press releases

In the news

Who we are
Careers
- Culture
- Job Openings
Investors
SEC filings

Quarterly results

Annual reports

Stock information

Analyst coverage

ESG information
Governance overview

Board of directors

Committee composition

Leadership

ESG information

Annual reports
Investor FAQs

Information request

Email alerts

Annual reports

Press Releases

Items Per Page

Year

Apr 20, 2021

Veracyte to Release First Quarter 2021 Financial Results on May 10, 2021

Read More

Apr 19, 2021

Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference

Read More

Apr 15, 2021

Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results

Read More

Apr 14, 2021

Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test

Read More

Apr 02, 2021

Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference

Read More

Mar 22, 2021

Veracyte Appoints Muna Bhanji to Its Board of Directors

Read More

Mar 15, 2021

Veracyte Completes Acquisition of Decipher Biosciences

Read More

Mar 10, 2021

Veracyte Commends New USPSTF Lung Cancer Screening Guidelines

Read More

Feb 18, 2021

Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference

Read More

Feb 17, 2021

Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results

Read More

Pagination

First page
Previous page
…
Page 16
Page 17
Current page 18
Page 19
Page 20
…
Next page
Last page

Displaying 171 - 180 of 514

Contact Investor Relations

Please feel free to contact us if you have questions or would like additional investor relations information:

investors@veracyte.com
+1 619.393.1545

Shareholder Tools

menu_book Printed Materials
print Print
share Share

Subscribe to Investor Alerts

Sign up

© 2024 Veracyte, Inc. All rights reserved.

Offices

South San Francisco, CA

6000 Shoreline Court, Suite 300
South San Francisco, CA 94080
Marseille, France

163 Avenue de Luminy
13009 Marseille
FRANCE
San Diego, CA

6925 Lusk Boulevard, Suite 200
San Diego, CA 92121
Austin, TX

12357-A Riata Trace Parkway
Building 5, Suite 100
Austin, TX 78727
Haifa, Israel

Nahum Het 7
3508506 Haifa, Israel
ISRAEL

Helpful links

Privacy Policy
HIPAA Notice of Privacy Practices (PDF)
Terms of Use
Terms of Sale
No Surprise Act
Business ethics and compliance
Accessibility
Cookie Settings

Connect

Contact
LinkedIn
X (Twitter)
YouTube

Facebook
Twitter
LinkedIn